PT2147096E - Polipéptidos do factor vii modificados e suas utilizações - Google Patents
Polipéptidos do factor vii modificados e suas utilizações Download PDFInfo
- Publication number
- PT2147096E PT2147096E PT87428520T PT08742852T PT2147096E PT 2147096 E PT2147096 E PT 2147096E PT 87428520 T PT87428520 T PT 87428520T PT 08742852 T PT08742852 T PT 08742852T PT 2147096 E PT2147096 E PT 2147096E
- Authority
- PT
- Portugal
- Prior art keywords
- fvii
- polypeptide
- amino acid
- modified
- fvii polypeptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 427
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 425
- 229920001184 polypeptide Polymers 0.000 title claims description 423
- 229940012413 factor vii Drugs 0.000 title claims description 86
- 230000000694 effects Effects 0.000 claims description 139
- 150000001413 amino acids Chemical class 0.000 claims description 120
- 108010000499 Thromboplastin Proteins 0.000 claims description 118
- 108090000623 proteins and genes Proteins 0.000 claims description 117
- 102000004169 proteins and genes Human genes 0.000 claims description 103
- 230000004048 modification Effects 0.000 claims description 94
- 238000012986 modification Methods 0.000 claims description 94
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 89
- 108010023321 Factor VII Proteins 0.000 claims description 88
- 230000027455 binding Effects 0.000 claims description 81
- 210000004027 cell Anatomy 0.000 claims description 78
- 150000007523 nucleic acids Chemical class 0.000 claims description 77
- 102000039446 nucleic acids Human genes 0.000 claims description 76
- 108020004707 nucleic acids Proteins 0.000 claims description 76
- 230000015271 coagulation Effects 0.000 claims description 72
- 238000005345 coagulation Methods 0.000 claims description 72
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 71
- 102000035195 Peptidases Human genes 0.000 claims description 68
- 108091005804 Peptidases Proteins 0.000 claims description 68
- 108090000190 Thrombin Proteins 0.000 claims description 60
- 229960004072 thrombin Drugs 0.000 claims description 60
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims description 56
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims description 56
- 239000004365 Protease Substances 0.000 claims description 55
- 230000001965 increasing effect Effects 0.000 claims description 55
- 150000003904 phospholipids Chemical class 0.000 claims description 51
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 49
- 108010014173 Factor X Proteins 0.000 claims description 44
- 229940012426 factor x Drugs 0.000 claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 108010076282 Factor IX Proteins 0.000 claims description 39
- 229960004222 factor ix Drugs 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 34
- 102000004411 Antithrombin III Human genes 0.000 claims description 32
- 108090000935 Antithrombin III Proteins 0.000 claims description 32
- 229960005348 antithrombin iii Drugs 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 28
- 208000009292 Hemophilia A Diseases 0.000 claims description 27
- 230000003197 catalytic effect Effects 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 27
- 238000006467 substitution reaction Methods 0.000 claims description 24
- 239000000701 coagulant Substances 0.000 claims description 23
- 208000032843 Hemorrhage Diseases 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 208000031220 Hemophilia Diseases 0.000 claims description 17
- 208000034158 bleeding Diseases 0.000 claims description 16
- 230000000740 bleeding effect Effects 0.000 claims description 16
- 230000001419 dependent effect Effects 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 208000014674 injury Diseases 0.000 claims description 15
- 238000003780 insertion Methods 0.000 claims description 15
- 230000037431 insertion Effects 0.000 claims description 15
- 239000001630 malic acid Substances 0.000 claims description 15
- 102100027378 Prothrombin Human genes 0.000 claims description 14
- 108010094028 Prothrombin Proteins 0.000 claims description 14
- 229940039716 prothrombin Drugs 0.000 claims description 14
- 102200066497 rs35629723 Human genes 0.000 claims description 14
- 230000023555 blood coagulation Effects 0.000 claims description 13
- 230000013595 glycosylation Effects 0.000 claims description 13
- 238000006206 glycosylation reaction Methods 0.000 claims description 13
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 13
- 239000003805 procoagulant Substances 0.000 claims description 13
- 102220521254 Lysosomal protective protein_K197L_mutation Human genes 0.000 claims description 12
- 208000009429 hemophilia B Diseases 0.000 claims description 12
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 101800004937 Protein C Proteins 0.000 claims description 10
- 102000017975 Protein C Human genes 0.000 claims description 10
- 101800001700 Saposin-D Proteins 0.000 claims description 10
- 230000004481 post-translational protein modification Effects 0.000 claims description 10
- 229960000856 protein c Drugs 0.000 claims description 10
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 8
- 102220024780 rs199473488 Human genes 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 229940096437 Protein S Drugs 0.000 claims description 6
- 108010066124 Protein S Proteins 0.000 claims description 6
- 102000029301 Protein S Human genes 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 230000003462 zymogenic effect Effects 0.000 claims description 6
- 101150022345 GAS6 gene Proteins 0.000 claims description 5
- 102220603448 Homeobox protein SIX3_A34R_mutation Human genes 0.000 claims description 5
- 102000004067 Osteocalcin Human genes 0.000 claims description 5
- 108090000573 Osteocalcin Proteins 0.000 claims description 5
- 102220493749 Paired box protein Pax-6_I42S_mutation Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 230000002008 hemorrhagic effect Effects 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 241000699800 Cricetinae Species 0.000 claims description 4
- 102220536010 Dynamin-1-like protein_K38A_mutation Human genes 0.000 claims description 4
- 102220516207 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial_K38T_mutation Human genes 0.000 claims description 4
- 102220523133 Eukaryotic translation initiation factor 4E-binding protein 2_T37E_mutation Human genes 0.000 claims description 4
- 102220603445 Homeobox protein SIX3_K32T_mutation Human genes 0.000 claims description 4
- 102220540445 Ovarian cancer-related protein 1_Y44S_mutation Human genes 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 102200159067 c.130T>A Human genes 0.000 claims description 4
- 125000003636 chemical group Chemical group 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 230000005847 immunogenicity Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 102220603436 Homeobox protein SIX3_K32A_mutation Human genes 0.000 claims description 3
- 102220467432 Protein Jade-1_K38S_mutation Human genes 0.000 claims description 3
- 229940030225 antihemorrhagics Drugs 0.000 claims description 3
- 208000011664 congenital factor XI deficiency Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000007219 factor XI deficiency Diseases 0.000 claims description 3
- 210000003292 kidney cell Anatomy 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 102220635301 Adenylate kinase isoenzyme 6_I42R_mutation Human genes 0.000 claims description 2
- 102220617593 B1 bradykinin receptor_K38R_mutation Human genes 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 102220594399 HLA class I histocompatibility antigen, C alpha chain_D33S_mutation Human genes 0.000 claims description 2
- 208000023661 Haematological disease Diseases 0.000 claims description 2
- 102220603449 Homeobox protein SIX3_A34S_mutation Human genes 0.000 claims description 2
- 102220603453 Homeobox protein SIX3_A34W_mutation Human genes 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 102220631868 Regulator of G-protein signaling 2_W41D_mutation Human genes 0.000 claims description 2
- 102220494687 Small vasohibin-binding protein_R36E_mutation Human genes 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 201000007386 factor VII deficiency Diseases 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 230000000025 haemostatic effect Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 108010025221 plasma protein Z Proteins 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 102220033735 rs104886489 Human genes 0.000 claims description 2
- 102220249718 rs1553408194 Human genes 0.000 claims description 2
- 102200020878 rs73015965 Human genes 0.000 claims description 2
- 102220234199 rs746624223 Human genes 0.000 claims description 2
- 102220064446 rs786205841 Human genes 0.000 claims description 2
- 102200057185 rs863225150 Human genes 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 102100030859 Tissue factor Human genes 0.000 claims 3
- 102220550001 T-cell immunoreceptor with Ig and ITIM domains_I42A_mutation Human genes 0.000 claims 2
- 102220076035 rs147623032 Human genes 0.000 claims 2
- 102220473763 Beta-adrenergic receptor kinase 1_D3K_mutation Human genes 0.000 claims 1
- 102220641809 E3 ubiquitin-protein ligase parkin_S65E_mutation Human genes 0.000 claims 1
- 102220516214 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial_T37C_mutation Human genes 0.000 claims 1
- 102220594400 HLA class I histocompatibility antigen, C alpha chain_D33F_mutation Human genes 0.000 claims 1
- 102220469874 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN_A34D_mutation Human genes 0.000 claims 1
- 241000235061 Pichia sp. Species 0.000 claims 1
- 102220549527 Polyubiquitin-C_S65D_mutation Human genes 0.000 claims 1
- 102220547369 Protein APCDD1_L65S_mutation Human genes 0.000 claims 1
- 102220550867 Purkinje cell protein 2 homolog_K42H_mutation Human genes 0.000 claims 1
- 102220414499 c.131A>G Human genes 0.000 claims 1
- 102200102393 c.194T>A Human genes 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 102220004442 rs121918685 Human genes 0.000 claims 1
- 102220321823 rs1554812271 Human genes 0.000 claims 1
- 102220020898 rs1800062 Human genes 0.000 claims 1
- 102220005499 rs33938574 Human genes 0.000 claims 1
- 102220139548 rs61735306 Human genes 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 210
- 235000001014 amino acid Nutrition 0.000 description 146
- 102000002262 Thromboplastin Human genes 0.000 description 115
- 229940024606 amino acid Drugs 0.000 description 111
- 239000001272 nitrous oxide Substances 0.000 description 105
- 235000018102 proteins Nutrition 0.000 description 98
- 101150108358 GLAA gene Proteins 0.000 description 84
- 101150014526 Gla gene Proteins 0.000 description 84
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 83
- 210000001772 blood platelet Anatomy 0.000 description 77
- 238000001994 activation Methods 0.000 description 51
- 230000004913 activation Effects 0.000 description 45
- 235000019419 proteases Nutrition 0.000 description 42
- 102220033048 rs62645931 Human genes 0.000 description 39
- 238000000034 method Methods 0.000 description 38
- 102220500235 Coagulation factor VII_K197E_mutation Human genes 0.000 description 37
- 102000010911 Enzyme Precursors Human genes 0.000 description 37
- 108010062466 Enzyme Precursors Proteins 0.000 description 37
- 238000003776 cleavage reaction Methods 0.000 description 35
- 230000000875 corresponding effect Effects 0.000 description 35
- 230000007017 scission Effects 0.000 description 35
- 108010073385 Fibrin Proteins 0.000 description 33
- 102000009123 Fibrin Human genes 0.000 description 33
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 33
- 125000000539 amino acid group Chemical group 0.000 description 33
- 229950003499 fibrin Drugs 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 32
- 239000003112 inhibitor Substances 0.000 description 28
- 239000002243 precursor Substances 0.000 description 28
- 230000002797 proteolythic effect Effects 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 230000037361 pathway Effects 0.000 description 24
- 108010022999 Serine Proteases Proteins 0.000 description 23
- 102000012479 Serine Proteases Human genes 0.000 description 23
- 230000003993 interaction Effects 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 21
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 20
- 108090000317 Chymotrypsin Proteins 0.000 description 20
- 229960002376 chymotrypsin Drugs 0.000 description 20
- 108010013773 recombinant FVIIa Proteins 0.000 description 20
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 19
- 239000003114 blood coagulation factor Substances 0.000 description 19
- 241000894007 species Species 0.000 description 19
- 108010054218 Factor VIII Proteins 0.000 description 18
- 102000001690 Factor VIII Human genes 0.000 description 18
- 229960000301 factor viii Drugs 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 230000023597 hemostasis Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 238000001356 surgical procedure Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 229940068953 recombinant fviia Drugs 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- -1 for example Proteins 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 101800003838 Epidermal growth factor Proteins 0.000 description 14
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 14
- 231100000319 bleeding Toxicity 0.000 description 14
- 230000009073 conformational modification Effects 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 229940116977 epidermal growth factor Drugs 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 230000035602 clotting Effects 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 230000006337 proteolytic cleavage Effects 0.000 description 12
- 102100036537 von Willebrand factor Human genes 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 11
- 108010049003 Fibrinogen Proteins 0.000 description 11
- 102000008946 Fibrinogen Human genes 0.000 description 11
- 229940012952 fibrinogen Drugs 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 108010047303 von Willebrand Factor Proteins 0.000 description 11
- 206010010356 Congenital anomaly Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 108010016054 tissue-factor-pathway inhibitor 2 Proteins 0.000 description 10
- 102000055046 tissue-factor-pathway inhibitor 2 Human genes 0.000 description 10
- 229960001134 von willebrand factor Drugs 0.000 description 10
- 229930003448 Vitamin K Natural products 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 9
- 230000002947 procoagulating effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 235000019168 vitamin K Nutrition 0.000 description 9
- 239000011712 vitamin K Substances 0.000 description 9
- 150000003721 vitamin K derivatives Chemical class 0.000 description 9
- 229940046010 vitamin k Drugs 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 108010088842 Fibrinolysin Proteins 0.000 description 8
- 108090001126 Furin Proteins 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 230000021523 carboxylation Effects 0.000 description 8
- 238000006473 carboxylation reaction Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 229940012957 plasmin Drugs 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 7
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000010118 platelet activation Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 6
- 108010054265 Factor VIIa Proteins 0.000 description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 6
- 241000282575 Gorilla Species 0.000 description 6
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 230000020764 fibrinolysis Effects 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 230000002439 hemostatic effect Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- 230000006624 extrinsic pathway Effects 0.000 description 5
- 230000033444 hydroxylation Effects 0.000 description 5
- 238000005805 hydroxylation reaction Methods 0.000 description 5
- 230000006623 intrinsic pathway Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 241000252212 Danio rerio Species 0.000 description 4
- 102000012545 EGF-like domains Human genes 0.000 description 4
- 108050002150 EGF-like domains Proteins 0.000 description 4
- 102000004961 Furin Human genes 0.000 description 4
- 102100035233 Furin Human genes 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000282576 Pan paniscus Species 0.000 description 4
- 241000282577 Pan troglodytes Species 0.000 description 4
- 102000001938 Plasminogen Activators Human genes 0.000 description 4
- 108010001014 Plasminogen Activators Proteins 0.000 description 4
- 241000282405 Pongo abelii Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 229940012414 factor viia Drugs 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102100037642 Elongation factor G, mitochondrial Human genes 0.000 description 3
- 108010074860 Factor Xa Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101000880344 Homo sapiens Elongation factor G, mitochondrial Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 102000008847 Serpin Human genes 0.000 description 3
- 108050000761 Serpin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012707 chemical precursor Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 229940112216 novoseven Drugs 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 229940127126 plasminogen activator Drugs 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000003001 serine protease inhibitor Substances 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- YDBVAWZTOAZPTJ-REOHCLBHSA-N (2s)-2-(hydroxyamino)butanedioic acid Chemical compound ON[C@H](C(O)=O)CC(O)=O YDBVAWZTOAZPTJ-REOHCLBHSA-N 0.000 description 2
- 102220491410 ADP-ribosylation factor-like protein 16_T37N_mutation Human genes 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010048623 Collagen Receptors Proteins 0.000 description 2
- 102000016511 Cyclic GMP-Dependent Protein Kinase Type I Human genes 0.000 description 2
- 108010067530 Cyclic GMP-Dependent Protein Kinase Type I Proteins 0.000 description 2
- 102220636170 Cystatin-A_I42A_mutation Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010048049 Factor IXa Proteins 0.000 description 2
- 108010071241 Factor XIIa Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 2
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 2
- 101100226845 Strongylocentrotus purpuratus EGF2 gene Proteins 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108010079274 Thrombomodulin Proteins 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- 208000037919 acquired disease Diseases 0.000 description 2
- 208000013633 acquired hemophilia Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 238000010523 cascade reaction Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940099816 human factor vii Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 150000008106 phosphatidylserines Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000003331 prothrombotic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000015139 regulation of coagulation Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 102200153433 rs104894817 Human genes 0.000 description 2
- 102220057308 rs730881066 Human genes 0.000 description 2
- 102220071724 rs794728408 Human genes 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 102000004149 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 1
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 1
- 101710082751 Carboxypeptidase S1 homolog A Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000252506 Characiformes Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108050006018 Coagulation factor VII Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000334290 Diodon holocanthus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101100126130 Escherichia coli O111:H- insE gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010016077 Factor IX deficiency Diseases 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102220471770 Fructose-bisphosphate aldolase A_E82Q_mutation Human genes 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 208000013607 Glanzmann thrombasthenia Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010054964 H-hexahydrotyrosyl-alanyl-arginine-4-nitroanilide Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102220570133 Histone PARylation factor 1_K32Q_mutation Human genes 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 241000485664 Protortonia cacti Species 0.000 description 1
- 102220611719 RNA polymerase I-specific transcription initiation factor RRN3_R28E_mutation Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108090000083 Serine Endopeptidases Proteins 0.000 description 1
- 102000003667 Serine Endopeptidases Human genes 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 241001441722 Takifugu rubripes Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000035100 Threonine proteases Human genes 0.000 description 1
- 108091005501 Threonine proteases Proteins 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102220479730 Tissue-type plasminogen activator_A34D_mutation Human genes 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000004208 acquired thrombocytopenia Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000008841 allosteric interaction Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108010083526 asialo-von Willebrand Factor Proteins 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000007364 biochemical regulatory process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004303 calcium sorbate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940043292 chymotrypsin / trypsin Drugs 0.000 description 1
- 108010055222 clotting enzyme Proteins 0.000 description 1
- 229940105772 coagulation factor vii Drugs 0.000 description 1
- 102000021124 collagen binding proteins Human genes 0.000 description 1
- 108091011142 collagen binding proteins Proteins 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 102220500037 eIF5-mimic protein 2_K32G_mutation Human genes 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 230000009843 endothelial lesion Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 108010013113 glutamyl carboxylase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000002085 hemarthrosis Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000031209 hemophilic arthropathy Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229930185896 leporin Natural products 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000415 mammalian chromosome Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229940124553 radioprotectant Drugs 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102220095974 rs149101834 Human genes 0.000 description 1
- 102220276595 rs1553131446 Human genes 0.000 description 1
- 102220253478 rs1553261891 Human genes 0.000 description 1
- 102220071725 rs199473488 Human genes 0.000 description 1
- 102220249828 rs267606858 Human genes 0.000 description 1
- 102220114727 rs372166877 Human genes 0.000 description 1
- 102220139812 rs373610655 Human genes 0.000 description 1
- 102220037197 rs587780270 Human genes 0.000 description 1
- 102220275968 rs750027302 Human genes 0.000 description 1
- 102220323551 rs771587118 Human genes 0.000 description 1
- 102220217756 rs777095030 Human genes 0.000 description 1
- 102220272417 rs80357066 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000007056 transamidation reaction Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000007556 vascular defect Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92351207P | 2007-04-13 | 2007-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2147096E true PT2147096E (pt) | 2015-07-21 |
Family
ID=39689319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT87428520T PT2147096E (pt) | 2007-04-13 | 2008-04-11 | Polipéptidos do factor vii modificados e suas utilizações |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20100166729A9 (enExample) |
| EP (2) | EP2147096B1 (enExample) |
| JP (3) | JP5761782B2 (enExample) |
| KR (2) | KR20100016462A (enExample) |
| CN (2) | CN101743309B (enExample) |
| AU (1) | AU2008239586B2 (enExample) |
| BR (1) | BRPI0810172A2 (enExample) |
| CA (1) | CA2683443A1 (enExample) |
| CO (1) | CO6231052A2 (enExample) |
| CR (1) | CR11058A (enExample) |
| DK (1) | DK2147096T3 (enExample) |
| EC (1) | ECSP099735A (enExample) |
| ES (1) | ES2537328T3 (enExample) |
| GT (1) | GT200900268A (enExample) |
| HN (1) | HN2009002098A (enExample) |
| IL (2) | IL201173A0 (enExample) |
| MX (1) | MX2009010997A (enExample) |
| NI (1) | NI200900187A (enExample) |
| NZ (2) | NZ579985A (enExample) |
| PH (1) | PH12014501960A1 (enExample) |
| PL (1) | PL2147096T3 (enExample) |
| PT (1) | PT2147096E (enExample) |
| RU (1) | RU2571931C2 (enExample) |
| SG (1) | SG174077A1 (enExample) |
| SI (1) | SI2147096T1 (enExample) |
| SV (1) | SV2009003393A (enExample) |
| UA (1) | UA101155C2 (enExample) |
| WO (1) | WO2008127702A2 (enExample) |
| ZA (2) | ZA200906854B (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| US7939304B2 (en) * | 2002-10-02 | 2011-05-10 | Catalyst Biosciences, Inc. | Mutant MT-SP1 proteases with altered substrate specificity or activity |
| AU2003282724B2 (en) * | 2002-10-02 | 2010-03-04 | Catalyst Biosciences, Inc. | Methods of generating and screening for proteases with altered specificity |
| JP5629423B2 (ja) * | 2004-04-12 | 2014-11-19 | カタリスト バイオサイエンシーズ， インコーポレイテッド | 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断 |
| JP5219819B2 (ja) * | 2005-10-21 | 2013-06-26 | カタリスト・バイオサイエンシーズ・インコーポレイテッド | 補体活性化を阻害する修飾プロテアーゼ |
| EP2423307A1 (en) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IV polypeptides and use thereof for treatment |
| SG175602A1 (en) | 2006-07-05 | 2011-11-28 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
| CA2683443A1 (en) * | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides and uses thereof |
| TWI465247B (zh) * | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| EP2177624A1 (en) * | 2008-10-02 | 2010-04-21 | Siemens Healthcare Diagnostics Products GmbH | Blood coagulation assays |
| JP5909180B2 (ja) * | 2009-06-25 | 2016-04-26 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | キメラ第ｖｉｉ因子分子 |
| GB0916578D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| CN103221061A (zh) | 2010-10-06 | 2013-07-24 | 米迪缪尼有限公司 | 用于治疗止血障碍的因子ii以及纤维蛋白原 |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| WO2012048276A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
| TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| WO2012149463A1 (en) * | 2011-04-29 | 2012-11-01 | The University Of North Carolina At Chapel Hill | Chimeric factor vii molecules with enhanced half life and methods of use |
| EP2554161A1 (en) | 2011-08-02 | 2013-02-06 | LFB Biotechnologies | Pharmaceutical composition comprising factor VII encapsulated in micelles |
| CN104271150A (zh) * | 2012-01-12 | 2015-01-07 | 比奥根艾迪克Ma公司 | 嵌合因子viii多肽及其用途 |
| MY190257A (en) | 2012-04-16 | 2022-04-11 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
| WO2013177584A2 (en) * | 2012-05-25 | 2013-11-28 | The Children's Hospital Of Philadelphia | FVIIa VARIANTS EXHIBITING ALTERED INTERACTION WITH ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) AND METHODS OF USE THEREOF FOR MODULATING HEMOSTASIS |
| US8986991B2 (en) * | 2012-07-03 | 2015-03-24 | Expression Therapeutics, Llc | High yield suspension cell line, system and method for making same |
| WO2014018120A1 (en) | 2012-07-25 | 2014-01-30 | Catalyst Biosciences, Inc. | Modified factor x polypeptides and uses thereof |
| CN104661685A (zh) | 2012-10-15 | 2015-05-27 | 诺和诺德保健Ag（股份有限公司） | 因子vii缀合物 |
| BR112015021866A2 (pt) | 2013-03-15 | 2017-08-29 | Bayer Healthcare Llc | Domínios de gla como agentes direcionadores |
| EP3003391B1 (en) | 2013-05-31 | 2021-09-22 | The Regents of The University of California | Adeno-associated virus variants and methods of use thereof |
| CN103397009B (zh) * | 2013-08-16 | 2015-06-03 | 安源生物科技(上海)有限公司 | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 |
| CA2927756A1 (en) | 2013-10-15 | 2015-04-23 | Novo Nordisk Health Care Ag | Coagulation factor vii polypeptides |
| WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| EA202190813A1 (ru) * | 2014-05-26 | 2021-12-31 | Академиш Зикенхёйс Лейден | Прогемостатические белки для лечения кровотечений |
| EP3198006B1 (en) | 2014-09-26 | 2021-03-24 | Terumo BCT, Inc. | Scheduled feed |
| US11021519B2 (en) | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| JP6836999B2 (ja) | 2015-03-24 | 2021-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | アデノ随伴ウイルス変異体及びその使用方法 |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| AU2017302013B2 (en) | 2016-07-29 | 2022-05-26 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| JP2020519272A (ja) * | 2017-05-09 | 2020-07-02 | エモリー ユニバーシティー | 凝固因子変異体及びその使用 |
| WO2018222503A1 (en) * | 2017-05-31 | 2018-12-06 | The Regents Of The University Of California | Adeno-associated virus with variant capsid and methods of use thereof |
| CA3053154A1 (en) | 2017-06-30 | 2019-01-03 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsids and methods of use thereof |
| JP2020534788A (ja) | 2017-08-28 | 2020-12-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アデノ随伴ウイルスカプシド変異体及びその使用方法 |
| EP3679129A1 (en) | 2017-09-05 | 2020-07-15 | GLAdiator Biosciences, Inc. | A method of intracellular delivery |
| PL3793588T3 (pl) | 2018-05-18 | 2025-09-01 | Bioverativ Therapeutics Inc. | Sposoby leczenia hemofilii a |
| WO2020028886A1 (en) * | 2018-08-03 | 2020-02-06 | Duke University | Protein c-factor vii chimeras |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
| EP4314244B1 (en) | 2021-03-23 | 2025-07-23 | Terumo BCT, Inc. | Cell capture and expansion |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| EP4704876A2 (en) * | 2023-05-04 | 2026-03-11 | The Cleveland Clinic Foundation | Human factor vii deletion constructs for treating cancer |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5033352A (en) | 1989-01-19 | 1991-07-23 | Yamaha Corporation | Electronic musical instrument with frequency modulation |
| US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| ATE180834T1 (de) * | 1990-01-29 | 1999-06-15 | Zymogenetics Inc | Antikoagulierende proteine |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| US20040087498A1 (en) * | 1991-02-28 | 2004-05-06 | Novo Nordisk Health Care Ag | Modified factor VII |
| US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6344596B1 (en) | 1997-02-14 | 2002-02-05 | American Red Cross | Expression of active human factor IX in mammary tissue and of milk non human transgenic mammals |
| US20050032690A1 (en) * | 1997-09-10 | 2005-02-10 | Rojkjaer Lisa Payne | Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
| US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| DE19937219A1 (de) | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie |
| WO2001032711A2 (en) | 1999-10-21 | 2001-05-10 | Board Of Trustees Of The University Of Arkansas | Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| CA2739933A1 (en) * | 2000-02-11 | 2001-08-16 | Bayer Healthcare Llc | Factor vii or viia-like molecules |
| US6905683B2 (en) * | 2000-05-03 | 2005-06-14 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
| JP4455802B2 (ja) | 2000-05-03 | 2010-04-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト第ｖｉｉ凝固因子変異型 |
| JP2004505016A (ja) * | 2000-05-10 | 2004-02-19 | ノボ ノルディスク アクティーゼルスカブ | 第ＶＩＩａ因子及び第ＸＩＩＩ因子を含んで成る医薬組成物 |
| WO2002022776A2 (en) | 2000-09-13 | 2002-03-21 | Novo Nordisk A/S | Human coagulation factor vii variants |
| MXPA03001984A (es) * | 2000-09-13 | 2003-08-29 | Novo Nordisk Healthcare Ag | Variantes de factor vii de coagulacion humano. |
| BR0114373A (pt) * | 2000-10-02 | 2004-02-17 | Novo Nordisk As | Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante |
| WO2002038162A1 (en) | 2000-11-09 | 2002-05-16 | The Scripps Research Institute | MODIFIED FACTOR VIIa |
| US6800453B2 (en) | 2001-01-23 | 2004-10-05 | President And Fellows Of Harvard College | Nucleic-acid programmable protein arrays |
| US20040133930A1 (en) | 2002-03-11 | 2004-07-08 | Cooper Julian D. | Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses |
| US7235638B2 (en) * | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
| CZ20032454A3 (en) | 2001-03-22 | 2004-03-17 | Novo Nordisk Health Care Ag | Coagulation factor vii derivative |
| AU2002315525A1 (en) * | 2001-07-03 | 2003-01-21 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon |
| US7419949B2 (en) * | 2001-07-16 | 2008-09-02 | Novo Noridsk Healthcare A/G | Single-dose administration of factor VIIa |
| US6882883B2 (en) * | 2001-08-31 | 2005-04-19 | Medtronic, Inc. | Implantable medical device (IMD) system configurable to subject a patient to a stress test and to detect myocardial ischemia within the patient |
| CZ2004427A3 (cs) | 2001-09-27 | 2004-08-18 | Novoánordiskáhealthácareáag | Polypeptidy lidského koagulačního faktoru VII |
| US7052868B2 (en) * | 2001-09-27 | 2006-05-30 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| EP1434857B1 (en) * | 2001-10-02 | 2007-08-01 | Novo Nordisk Health Care AG | Method for production of recombinant proteins in eukaryote cells |
| US20030143219A1 (en) * | 2001-10-09 | 2003-07-31 | Madison Edwin L | Nucleic acid molecules encoding a transmembrane serine protease 25, the encoded polypeptides and methods based thereon |
| JP3862996B2 (ja) | 2001-10-31 | 2006-12-27 | 帝人ファイバー株式会社 | ポリトリメチレンテレフタレートフィラメント糸およびその製造方法 |
| US6960657B2 (en) * | 2001-11-02 | 2005-11-01 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| US7291587B2 (en) * | 2001-11-09 | 2007-11-06 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides |
| AU2002357004A1 (en) * | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
| KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
| AU2002351755A1 (en) * | 2001-12-21 | 2003-07-15 | Novo Nordisk A/S | Liquid composition of modified factor vii polypeptides |
| WO2003093465A1 (en) * | 2002-04-30 | 2003-11-13 | Maxygen Holdings Ltd. | FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
| US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
| US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| DE60336555D1 (de) * | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
| AU2003247776A1 (en) * | 2002-07-02 | 2004-01-23 | Dendreon Corporation | Serine protease 16 |
| US6911323B2 (en) * | 2002-09-25 | 2005-06-28 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| JP4597678B2 (ja) | 2002-09-25 | 2010-12-15 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固因子ｖｉｉポリペプチド |
| CA2840692A1 (en) * | 2002-09-30 | 2004-04-08 | Bayer Healthcare Llc | Fvii or fviia variants having increased clotting activity |
| AU2003282724B2 (en) * | 2002-10-02 | 2010-03-04 | Catalyst Biosciences, Inc. | Methods of generating and screening for proteases with altered specificity |
| CA2519873C (en) * | 2003-03-20 | 2012-12-18 | Maxygen Holdings Ltd. | Fvii or fviia variants |
| FI20030413L (fi) | 2003-03-20 | 2004-09-21 | Suomen Intech Oy | Kaasulaakerointi |
| US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
| WO2004087933A2 (en) | 2003-03-28 | 2004-10-14 | The Regents Of The University Of California | A novel encoding method for 'one-bead one-compound' combinatorial libraries |
| CA2528239A1 (en) | 2003-06-05 | 2004-12-16 | Canadian Blood Services | Mutants of the factor vii epidermal growth factor domain |
| US20060116324A1 (en) * | 2003-06-13 | 2006-06-01 | Novo Nordisk Healthcare A/G | Novel formulations |
| RU2373282C2 (ru) | 2003-06-19 | 2009-11-20 | Байер Хелткэр Ллк | ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa |
| ES2381110T3 (es) * | 2003-09-09 | 2012-05-23 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación |
| EP1673453A2 (en) * | 2003-10-07 | 2006-06-28 | Novo Nordisk Health Care AG | Hybrid molecules having factor vii/viia activity |
| US20070072271A1 (en) * | 2004-01-07 | 2007-03-29 | Novo Nordisk Healthcare A/G | Method for the production of recombinant proteins |
| JP2007522805A (ja) | 2004-02-03 | 2007-08-16 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 新規化合物 |
| JP5629423B2 (ja) * | 2004-04-12 | 2014-11-19 | カタリスト バイオサイエンシーズ， インコーポレイテッド | 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断 |
| EP1761630A2 (en) * | 2004-06-21 | 2007-03-14 | Novo Nordisk Health Care AG | Glycosylation-disrupted factor vii variants |
| WO2006014253A2 (en) * | 2004-07-02 | 2006-02-09 | Genentech, Inc. | Factor viia variants |
| WO2006114105A2 (en) * | 2005-04-26 | 2006-11-02 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| JP5690047B2 (ja) * | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第ｖｉｉ因子ポリペプチド |
| EP1929005A1 (en) * | 2005-09-21 | 2008-06-11 | Novo Nordisk Health Care AG | Human coagulation factor vii polypeptides |
| JP5219819B2 (ja) * | 2005-10-21 | 2013-06-26 | カタリスト・バイオサイエンシーズ・インコーポレイテッド | 補体活性化を阻害する修飾プロテアーゼ |
| EP2423307A1 (en) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IV polypeptides and use thereof for treatment |
| SG175602A1 (en) * | 2006-07-05 | 2011-11-28 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
| CA2683443A1 (en) * | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides and uses thereof |
| TWI465247B (zh) * | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| JP5909180B2 (ja) * | 2009-06-25 | 2016-04-26 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | キメラ第ｖｉｉ因子分子 |
| TWI557135B (zh) * | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| WO2014018120A1 (en) * | 2012-07-25 | 2014-01-30 | Catalyst Biosciences, Inc. | Modified factor x polypeptides and uses thereof |
-
2008
- 2008-04-11 CA CA002683443A patent/CA2683443A1/en not_active Abandoned
- 2008-04-11 CN CN200880016982.6A patent/CN101743309B/zh not_active Expired - Fee Related
- 2008-04-11 EP EP08742852.0A patent/EP2147096B1/en active Active
- 2008-04-11 KR KR1020097023568A patent/KR20100016462A/ko not_active Abandoned
- 2008-04-11 SI SI200831442T patent/SI2147096T1/sl unknown
- 2008-04-11 SG SG2011058658A patent/SG174077A1/en unknown
- 2008-04-11 MX MX2009010997A patent/MX2009010997A/es active IP Right Grant
- 2008-04-11 BR BRPI0810172-8A2A patent/BRPI0810172A2/pt active Search and Examination
- 2008-04-11 CN CN201310367450XA patent/CN103451172A/zh active Pending
- 2008-04-11 KR KR1020157014839A patent/KR20150067772A/ko not_active Ceased
- 2008-04-11 PT PT87428520T patent/PT2147096E/pt unknown
- 2008-04-11 ES ES08742852.0T patent/ES2537328T3/es active Active
- 2008-04-11 US US12/082,662 patent/US20100166729A9/en not_active Abandoned
- 2008-04-11 AU AU2008239586A patent/AU2008239586B2/en not_active Ceased
- 2008-04-11 DK DK08742852.0T patent/DK2147096T3/da active
- 2008-04-11 WO PCT/US2008/004795 patent/WO2008127702A2/en not_active Ceased
- 2008-04-11 RU RU2009141510/10A patent/RU2571931C2/ru not_active IP Right Cessation
- 2008-04-11 NZ NZ579985A patent/NZ579985A/en unknown
- 2008-04-11 NZ NZ593611A patent/NZ593611A/en unknown
- 2008-04-11 JP JP2010503081A patent/JP5761782B2/ja not_active Expired - Fee Related
- 2008-04-11 PL PL08742852T patent/PL2147096T3/pl unknown
- 2008-04-11 EP EP12156573A patent/EP2481797A1/en not_active Withdrawn
- 2008-04-11 UA UAA200911564A patent/UA101155C2/ru unknown
-
2009
- 2009-09-24 IL IL201173A patent/IL201173A0/en unknown
- 2009-10-01 ZA ZA2009/06854A patent/ZA200906854B/en unknown
- 2009-10-08 CO CO09111636A patent/CO6231052A2/es unknown
- 2009-10-09 CR CR11058A patent/CR11058A/es not_active Application Discontinuation
- 2009-10-09 HN HN2009002098A patent/HN2009002098A/es unknown
- 2009-10-12 NI NI200900187A patent/NI200900187A/es unknown
- 2009-10-13 GT GT200900268A patent/GT200900268A/es unknown
- 2009-10-13 SV SV2009003393A patent/SV2009003393A/es unknown
- 2009-11-13 EC EC2009009735A patent/ECSP099735A/es unknown
-
2011
- 2011-12-13 ZA ZA2011/09181A patent/ZA201109181B/en unknown
-
2012
- 2012-03-22 IL IL218776A patent/IL218776A0/en unknown
-
2013
- 2013-10-23 JP JP2013220232A patent/JP2014042523A/ja not_active Withdrawn
-
2014
- 2014-09-01 PH PH12014501960A patent/PH12014501960A1/en unknown
-
2016
- 2016-03-17 JP JP2016054083A patent/JP2016155836A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2147096E (pt) | Polipéptidos do factor vii modificados e suas utilizações | |
| DK2281037T3 (en) | Factor VII polypeptides modified and uses thereof | |
| AU2013204377B2 (en) | Modified factor vii polypeptides and uses thereof | |
| AU2013203608B2 (en) | Factor vii polypeptides that are modified and uses thereof | |
| HK1134520B (en) | Modified factor vii polypeptides and uses thereof | |
| HK1174059A (en) | Modified factor vii polypeptides and uses thereof | |
| AU2015224596A1 (en) | Factor vii polypeptides that are modified and uses thereof |